Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah is predicted to be optimistic under third person as it has although missed slightly to their guidance for revenue this year, but despite this, Nyxoah's financial health and wealth in the industry is greatly attained and maintained through collaboration with academic partners and FDA (Food and Drug Administration) for suitable innovations in the market, to deliver bilateral neurostimulation therapy that addresses Obstructive Sleep Apnea (OSA) effectively. Overall, their growth prospects look promising, with strong projected revenue of €36-40M by FY 2026, higher than Street and current analyst estimates, and a low valuation multiple of 3x expected 2027 revenue, making them an attractive investment choice for the long-term.

Nyxoah is continuing with its U.S. launch and is actively hiring new sales reps, indicating positive progress; however, the company's recent PMA supplement for a software upgrade may not significantly impact financials. Additionally, its pursuit of a new CPT code could boost reimbursement; however, the company's net-revenue guidance for FY26 is steep and the balance sheet may need to be bolstered as it has potential to become a high-growth asset. Due to valuation compression in the medtech category, the PT has been lowered to $7.00, with a ~3x EV/revenue multiple applied to the FY27 revenue forecast.